目的 探討清腦降壓片聯(lián)合非洛地平緩釋片治療原發(fā)性高血壓的臨床療效。方法 選取2015年2月-2016年2月在上海市靜安區(qū)石門二路街道社區(qū)衛(wèi)生服務(wù)中心接受治療的原發(fā)性高血壓患者94例,按照治療方法的差別將所有患者分成對照組和治療組,每組各47例。對照組口服非洛地平緩釋片,10mg/次,1次/d。治療組在對照組治療的基礎(chǔ)上口服清腦降壓片,6片/次,3次/d。兩組均連續(xù)治療4周。觀察兩組的臨床療效,同時(shí)比較治療前后兩組舒張壓(DBP)、收縮壓(SBP)、腦利鈉肽(NT-ProBNP)、同型半胱氨酸(HCY)的變化情況。結(jié)果 治療后,對照組和治療組的總有效率為82.98%、95.74%,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,兩組患者SBP、DBP、HCY、NT-ProBNP均顯著降低,同組治療前后差異有統(tǒng)計(jì)學(xué)意義(P<0.05);且治療組這些觀察指標(biāo)的改善程度優(yōu)于對照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 清腦降壓片聯(lián)合非洛地平緩釋片治療原發(fā)性高血壓具有較好的臨床療效,可明顯降低血清HCY、NT-ProBNP水平,具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Qingnao Jiangya Tablets combined with Felodipine Sustained Release Tablets in treatment of primary hypertension. Methods Patients (94 cases) with primary hypertension in Shimen Two-Way Street Community Health Service Center of Jing'an District in Shanghai from February 2015 to February 2016 were enrolled in this study. According to the different treatment plans, patients were divided into control group (47 cases) and treatment group (47 cases). The patients in the control group were po administered with Felodipine Sustained Release Tablets, 10 mg/time, once daily. The patients in the treatment group were po administered with Qingnao Jiangya Tablets on the basis of control group, 6 tablets/time, three times daily. The patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and the changes of DBP, SBP, NT-ProBNP, and HCY in two groups were compared before and after treatment. Results After treatment, the efficacies in the control and treatment groups were 82.98% and 95.74%, respectively, and there were differences between two groups (P < 0.05). After treatment, SBP, DBP, HCY, and NT-ProBNP in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Qingnao Jiangya Tablets combined with Felodipine Sustained Release Tablets has clinical curative effect in treatment of primary hypertension, and can significantly reduce serum HCY, NT-ProBNP, which has a certain clinical application value.